Overview

Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma

Status:
Unknown status
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
To determine the safety and efficacy of Gliadel 3.85% wafers plus surgery and radiation with Temozolomide
Phase:
Phase 2
Details
Lead Sponsor:
Kentuckiana Cancer Institute
Collaborator:
Eisai Inc.
Treatments:
Carmustine
Dacarbazine
Temozolomide